Clinical Trial Update: A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study [Phase 2]

View source ↗

Summary

Phase 2, single-center trial evaluating third-line treatment with Fruquintinib plus Serplulimab in advanced non-liver-limited metastatic colorectal cancer; curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Fruquintinib (fruquintinib)
• Serplulimab (serplulimab)

Snippet

Sponsor: Fudan University | Conditions: Colorectal Cancer | Phase 2 | Status: RECRUITING